Detail akcie BB Biotech AG online

Business Summary: BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Financial Summary: BRIEF: For the three months ended 31 March 2025, BB BIOTECH AG revenues decreased 99% to SF1.4M. Net loss totaled SF240.9M vs. income of SF260.5M. Revenues reflect Investment Portfolio segment decrease of 99% to SF2.7M. Net loss reflects Unrealized Gains/Loss increase from SF0K to SF327.6M (expense), Foreign exchange losses increase from SF16K to SF1.5M (expense).